1. Scrip
  2. >>Business
  3. >>Strategy

Troubled Realm Therapeutics Selling Assets, Delisting From London AIM

 
• By Sten Stovall

US-based, UK-listed biotech says it is talking with 'interested parties' including those considering making an offer for the business.

AssetManagement
Clinical Failures Have Forced Realm To Seek Buyers • Source: Shutterstock

Realm Therapeutics PLC, which last November launched a strategic review, said it plans to sell assets for up to $10m to Urgo US Inc, delist from London's AIM market, while continuing to hold discussions with "interested parties" that might lead to a takeover offer. 

Updating on its efforts to seek strategic alternatives after its key asset failed in clincial trials, the Malvern, PA-based biotech said it agreed the sale of certain assets, including the Vashe wound care royalty stream, hypochlorous acid (HOCI) related equipment, intellectual property including know-how,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.